Cost of Goods Sold (Annual)

Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.

Xeris Biopharma Holdings, Inc. (XERS) had Cost of Goods Sold of $36.83M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$203.07M
Net Income	$-54.84M
Cost of Goods Sold	$36.83M
Gross Profit	$166.24M
Operating Expenses	$236.72M
Operating Income	$-33.65M
Non-Operating Income/Expense	$-23.46M
Pre-Tax Income	$-57.10M
Normalized Pre-Tax Income	$-57.10M
Income after Taxes	$-54.84M
Income from Continuous Operations	$-54.84M
Consolidated Net Income/Loss	$-54.84M
Normalized Income after Taxes	$-54.84M
EBIT	$-33.65M
EBITDA	$-18.01M
Weighted-Average Shares Outstanding (Basic)	146.77M
Weighted-Average Shares Outstanding (Diluted)	146.77M
Earnings per Share (EPS) (Basic)	$-0.37
Earnings per Share (EPS) (Diluted)	$-0.37
Balance Sheet Financials
Current Assets	$167.66M
Property, Plant, and Equipment	$5.56M
Long-Term Assets	$155.40M
Total Assets	$323.06M
Current Liabilities	$100.44M
Long-Term Debt	$217.01M
Long-Term Liabilities	$252.23M
Total Liabilities	$352.68M
Common Equity	$-29.61M
Tangible Shareholders Equity	$-151.40M
Shareholders Equity	$-29.61M
Common Shares Outstanding	149.43M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-36.98M
Cash Flow from Investing Activities	$4.88M
Cash Flow from Financial Activities	$36.17M
Beginning Cash	$71.67M
End Cash	$75.74M
Increase/Decrease in Cash	$4.07M
Stock-Based Compensation	$18.36M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.67
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	1.16
Debt to Equity Ratio	-7.84
Gross Margin	81.86%
Operating Margin	-16.57%
EBIT Margin	-16.57%
EBITDA Margin	-8.87%
Pre-Tax Profit Margin	-28.12%
Profit Margin	-27.00%
Free Cash Flow	$-37.85M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.63
Inventory Turnover	0.76
Receiveable Turnover	5.02
Days Sales in Receivables	72.64
Return on Equity	185.16%
Return on Tangible Equity	36.22%
Return on Assets	-16.97%
Return on Investments	-29.26%
Book Value Per Share	$-0.20
Free Cash Flow per Share	$-0.26
Operating Cash Flow per Share	$-0.25

Data from Zacks Investment Research, Inc.